Review Proposal - February 2014
Review of NICE Technology Appraisal Guidance No.218; Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Proposal to move the existing guidance to the static list
The planned date for review of the above guidance is February 2014.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has been identified that is likely to lead to a change in the existing recommendations. Consequently we propose that TA218 should move to the static list of technology appraisals.
Topics on the static list may be transferred back to the active list for further consideration if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance. Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 17 February 2014